Antipsychotics in the treatment of autism

Journal of Clinical Investigation

Volumn 118, Issue 1, 2008, Pages 6-14

  Posey, David J ^a   Stigler, Kimberly A ^a   Erickson, Craig A ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; MOLINDONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPERIDOL; ZIPRASIDONE;

AGGRESSION; AGITATION; ASPERGER SYNDROME; AUTISM; AUTOMUTILATION; CHILDHOOD DISINTEGRATIVE DISORDER; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; HYPERSALIVATION; IRRITABILITY; NEUROTRANSMISSION; ONSET AGE; PRIORITY JOURNAL; RETT SYNDROME; REVIEW; SEDATION; SIDE EFFECT; WEIGHT GAIN;

AGGRESSION; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; DYSKINESIA, DRUG-INDUCED; HUMANS; SELF MUTILATION; WEIGHT GAIN;

EID: 38149021973     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32483     Document Type: Review

References (96)

1. Muhle, R., Trentacoste, S.V., and Rapin, I. 2004. The genetics of autism. Pediatrics. 113:e472-e486.
2. McDougle, C.J., Erickson, C.A., Stigler, K.A., and Posey, D.J. 2005. Neurochemistry in the pathophysiology of autism. J. Clin. Psychiatry. 66(Suppl. 10):9-18.
3. DiMartino, A., and Castellanos, F.X. 2003. Functional neuroimaging of social cognition in pervasive developmental disorders: a brief review. Ann. N. Y. Acad. Sci. 1008:256-260.
4. Allen, G., Müller, R., and Courchesne, E. 2004. Cerebellar function in autism: functional magnetic resonance image activation during a simple motor task. Biol. Psychiatry. 56:269-278.
5. Schultz, R.T., et al. 2000. Abnormal ventral temporal cortical activity during face discrimination among individuals with autism and Asperger syndrome. Arch. Gen. Psychiatry. 57:331-340.
6. Sweeten, T.L., Posey, D.J., Shekhar, A., McDougle, C.J. 2002. The amygdala and related structures in the pathophysiology of autism. Pharmacol. Biochem. Behav. 71:449-455.
7. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Publishing Inc. Arlington, Virginia, USA. 886 pp.
8. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators, and Centers for Disease Control and Prevention. 2007. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR Surveill. Summ. 56:12-28.
9. Lecavalier, L. 2006. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J. Autism Dev. Disord. 36:1101-1114.
10. Aman, M.G., Lam, K.S.L., and Van Bourgondien, M.E. 2005. Medication patterns in patients with autism: temporal, regional, and demographic influences. J. Child Adolesc. Psychopharmacol. 15:116-126.
11. Witwer, A., and Lecavalier, L. 2005. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J. Child Adolesc. Psychopharmacol. 15:671-681.
12. Posey, D.J., and McDougle, C.J. 2000. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv. Rev. Psychiatry. 8:45-63.
13. McDougle, C.J., et al. 1998. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry. 55:633-641.
14. Campbell, M., et al. 1978. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J. Am. Acad. Child Psychiatry. 17:640-655.
15. Research Units on Pediatric Psychopharmacology Autism Network. 2002. Risperidone in children with autism and serious behavioral problems. New Engl. J. Med. 347:314-321.
16. Shea, S., et al. 2004. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 114:e634-e641.
17. Moore, R.Y., and Bloom, F.E. 1979. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Ann. Rev. Neurosci. 2:113-168.
18. Campbell, M., et al. 1972. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J. Autism Child Schizophr. 2:343-358.
19. Campbell, M., et al. 1976. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr. Ther. Res. Clin. Exp. 19:70-86.
20. Launay, J.M., et al. 1987. Catecholamine metabolism in infantile autism: a controlled study of 22 autistic children. J. Autism Dev. Disord. 17:333-347.
21. Minderaa, R.B., et al. 1989. Neurochemical study of dopamine functioning in autistic and normal subjects. J. Am. Acad. Child Adolesc. Psychiatry. 28:200-206.
22. Maas, J.W., Hattox, S.E., Greene, N.M., and Landis, D.H. 1980. Estimates of dopamine and serotonin synthesis by the awake human brain. J. Neurochem. 34:1547-1549.
23. Narayan, M., Srinath, S., Anderson, G.M., and Meundi, D.B. 1993. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol. Psychiatry. 33:630-635.
24. Ross, D.L., Klykylo, W.M., and Anderson, G.M. 1985. Cerebrospinal fluid indoleamine and monoamine effects in fenfluramine treatment of autism. Ann. Neurol. 18:394.
25. Gillberg, C., and Svennerholm, L. 1987. CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br. J. Psychiatry. 151:89-94.
26. Comings, D.E., et al. 1991. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA. 266:1793-1800.
27. Robinson, P.D., Schutz, C.K., Macciardi, F., White, B.N., and Holden, J.J. 2001. Genetically determined low maternal serum dopamine β-hydroxylase levels and the etiology of autism spectrum disorders. Am. J. Med. Genet. 100:30-36.
28. Ernst, M., Zametkin, A.J., Matochik, J.A., Pascualvaca, D., and Cohen, R.M. 1997. Low medial prefrontal dopaminergic activity in autistic children. Lancet. 350:638.
29. Fernell, E., et al. 1997. Possible effects of tetrahydrobiopterin treatment in six children with autism - clinical and positron emission tomography data: a pilot study. Dev. Med. Child Neurol. 39:313-318.
30. Whitaker-Azmitia, P.M. 1993. The role of serotonin and serotonin receptors in development of the mammalian nervous system. In Receptors in the developing nervous system. Volume 2: Neurotransmitters. I.S. Zagon and P.J. McLaughlin, editors. Chapman & Hall. London, United Kingdom. 43-53.
31. Schain, R.J., and Freedman, D.X. 1961. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J. Pediatr. 58:315-320.
32. Ritvo, E.R., et al. 1970. Increased blood serotonin and platelets in early infantile autism. Arch. Gen. Psychiatry. 23:566-572.
33. Anderson, G.M., et al. 1987. Whole blood serotonin in autistic and normal subjects. J. Child Psychol. Psychiatry. 28:885-900.
34. McBride, P.A., et al. 1998. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry. 37:767-776.
35. Leboyer, M., et al. 1999. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol. Psychiatry. 45:158-163.
36. Hoshino, Y., et al. 1984. Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction. Jpn. J. Psychiatry Neurol. 26:937-945.
37. McBride, P.A., et al. 1989. Serotonergic responsivity in male young adults with autistic disorder: results of a pilot study. Arch. Gen. Psychiatry. 46:213-221.
38. McDougle, C.J., et al. 1996. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch. Gen. Psychiatry. 53:993-1000.
39. Cook, E.H., et al. 1997. Evidence of linkage between the serotonin transporter and autistic disorder. Mol. Psychiatry. 2:247-250.
40. Klauck, S.M., Poustka, F., Benner, A., Lesch, K.P., and Poustka, A. 1997. Serotonin transporter (5-HTT) gene variants associated with autism? Hum. Mol. Genet. 6:2233-2238.
41. McCauley, J.L., et al. 2004. Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127:104-112.
42. Mulder, E.J., et al. 2005. Serotonin transporter intron 2 polymorphism associated with rigid-compulsive behaviors in Dutch individuals with pervasive developmental disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133:93-96.
43. Chugani, D.C., et al. 1997. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann. Neurol. 42:666-669.
44. Chugani, D.C., et al. 1999. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann. Neurol. 45:287-295.
45. Campbell, M., Geller, B., and Cohen, I.L. 1977. Current status of drug research and treatment with autistic children. J. Pediatr. Psychol. 2:153-161.
46. Faretra, G., Dooher, L., and Dowling, J. 1970. Comparison of haloperidol and fluphenazine in disturbed children. Am. J. Psychiatry. 126:1670-1673.
47. Engelhardt, D.M., Polizos, P., Waizer, J., and Hoffman, S.P. 1973. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J. Autism Child Schizophr. 3:128-137.
48. Fish, B. 1985. Children's Psychiatric Rating Scale (scoring). Psychopharmacol. Bull. 21:753-764.
49. Cohen, I.L., et al. 1980. Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design. J. Am. Acad. Child Adolesc. Psychiatry. 19:665-677.
50. Anderson, L.T., et al. 1984. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am. J. Psychiatry. 141:1195-1202.
51. Anderson, L.T., et al. 1989. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J. Autism Dev. Disord. 19:227-239.
52. Perry, R., et al. 1989. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J. Am. Acad. Child Adolesc. Psychiatry. 28:87-92.
53. Campbell, M., et al. 1997. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry. 36:835-843.
54. Armenteros, J.L., Adams, P.B., Campbell, M., and Eisenberg, Z.W. 1995. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacol. Bull. 31:363-369.
55. Pierre, J.M. 2005. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 28: 191-208.
56. Chouinard, G., et al. 1993. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:25-40.
57. Fisman, S., and Steele, M. 1996. Use of risperidone in pervasive developmental disorders: a case series. J. Child Adolesc. Psychopharmacol. 6:177-190.
58. Zuddas, A., Ledda, M.G., Fratta, A., Muglia, P., and Cianchetti, C. 1996. Clinical effects of clozapine on autistic disorder (letter). Am. J. Psychiatry. 153:738.
59. Chen, N.C., Bedair, H.S., McKay, B., Bowers, M.B., Jr., and Mazure, C. 2001. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J. Clin. Psychiatry. 62:479-480.
60. Gobbi, G., and Pulvirenti, L. 2001. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. J. Psychiatry Neurosci. 26:340-341.
61. Aman, M.G., Singh, N.N., Stewart, A.W., and Field, C.J. 1985. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am. J. Ment. Defic. 5:485-491.
62. McDougle, C.J., et al. 2005. Risperidone for the core symptom domains of autism: results from the study by the autism network of the Research Units on Pediatric Psychopharmacology. Am. J. Psychiatry. 162:1142-1148.
63. Freeman, B.J., Ritvo, E.R., Yakota, A., and Ritvo, A. 1986. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J. Am. Acad. Child Adolesc. Psychiatry. 25:130-136.
64. Scahill, L., et al. 1997. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J. Am. Acad. Child Adolesc. Psychiatry 36:844-852.
65. Research Units on Pediatric Psychopharmacology Autism Network. 2005. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry. 162:1361-1369.
66. Troost, P.W., et al. 2005. Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J. Acad. Child Adolesc. Psychiatry. 44:1137-1144.
67. Schopler, E., Reichler, R.J., DeVellis, R.F., and Daly, K. 1980. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J. Autism Dev. Disord. 10:91-103.
68. Posey, D.J., Walsh, K.H., Wilson, G., and McDougle, C.J. 1999. Risperidone in the treatment of two very young children with autism. J. Child Adolesc. Psychopharmacol. 9:273-276.
69. Nagaraj, R., Singhi, P., and Malhi, P. 2006. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J. Child Neurol. 21:450-455.
70. Luby, J., et al. 2006. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J. Child Adolesc. Psychopharmacol. 16:575-587.
71. Potenza, M.N., Holmes, J.P., Kanes, S.J., and McDougle, C.J. 1999. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J. Clin. Psychopharmacol. 19:37-44.
72. Malone, R.P., Cater, J., Sheikh, R.M., Choudhury, M.S., and Delaney, M.A. 2001. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J. Am. Acad. Child Adolesc. Psychiatry. 40:887-894.
73. Kemner, C., Willemsen-Swinkels, S.H., de Jonge, M., Tuynman-Qua, H., and van Engeland, H. 2002. Open-label study of olanzapine in children with pervasive developmental disorder. J. Clin. Psychopharmacol. 22:455-460.
74. Hollander, E., et al. 2006. A double-blind placebo-controlled pilot study of olanzapine in childhood/ adolescent pervasive developmental disorder. J. Child Adolesc. Psychopharmacol. 16:541-548.
75. Martin, A., Koenig, K., Scahill, L., and Bregman, J. 1999. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J. Child Adolesc. Psychopharmacol. 9:99-107.
76. Findling, R.L., et al. 2004. Quetiapine in nine youths with autistic disorder. J. Child Adolesc. Psychopharmacol. 14:287-294.
77. Corson, A.H., Barkenbus, J.E., Posey, D.J., Stigler, K.A., and McDougle, C.J. 2004. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J. Clin. Psychiatry. 65:1531-1536.
78. Hardan, A.Y., Jou, R.J., and Handen, B.L. 2005. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J. Autism Dev. Disord. 35:387-391.
79. Goyette, C.H., Conners, C.K., and Ulrich, R.F. 1978. Normative data on revised Conners Parent and Teacher Rating Scales. J. Abnorm. Child Psychol. 6:221-236.
80. McDougle, C.J., Kem, D.L., and Posey, D.J. 2002. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J. Am. Acad. Child Adolesc. Psychiatry. 41:921-927.
81. Cohen, S.A., Fitzgerald, B.J., Khan, S.R., and Khan, A. 2004. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J. Clin. Psychiatry. 65:110-113.
82. Pfizer. 2007. Ziprasidone [package insert]. March revision. New York, New York, USA.
83. 2 receptors. J. Pharmacol. Exp. Ther. 302:381-389.
84. Stigler, K.A., Posey, D.J., and McDougle, C.J. 2004. Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder. J. Child Adolesc. Psychopharmacol. 14:455-463.
85. Stigler, K.A., et al. 2006. A prospective, open-label study of aripiprazole in youth with Asperger's disorder and pervasive developmental disorder not otherwise specified. Neuropsychopharmacology. 31:S194.
86. Stigler, K.A., Potenza, M.N., Posey, D.J., and McDougle, C.J. 2004. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Pediatric Drugs. 6:33-44.
87. Fedorow, V.J., and Fombonne, E. 2005. Metabolic side effects of atypical antipsychotics in children: a literature review. J. Psychopharmacol. 19:533-550.
88. Martin, A., et al. 2004. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am. J. Psychiatry. 161:1125-1127.
89. Anderson, G.M., et al. 2007. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol. Psychiatry. 61:545-550.
90. Findling, R.L., et al. 2003. Prolactin levels during long-term risperidone treatment in children and adolescents. J. Clin. Psychiatry 64:1362-1369.
91. Simpson, G.M., and Angus, J.W. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 212:11-19.
92. National Institute of Mental Health. 1985. Abnormal involuntary movement scale (AIMS). Psychopharmacol. Bull. 21:1077-1080.
93. Aman, M.G., et al. 2005. Acute and long-term safety and tolerability of risperidone in children with autism. J. Child. Adolesc. Psychopharmacol. 15:869-884.
94. Troost, P.W., et al. 2006. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. J. Child Adolesc. Psychopharmacol. 16:561-573.
95. Pandina, G.J., et al. 2007. Risperidone and cognitive function in children with disruptive behavior disorders. Biol. Psychiatry. 62:226-234.
96. McDougle, C.J., Stigler, K.A., and Posey, D.J. 2003. Treatment of aggression in children and adolescents with autism and conduct disorder. J. Clin. Psychiatry. 64(Suppl. 4):16-25.